Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial
Norheim KL, Ben Ezra M, Heckenbach I, et al. (2024). Nature Aging.
Summary
Forty patients with stable chronic obstructive pulmonary disease took the NAD+ precursor nicotinamide riboside or placebo for six weeks. The main measure was interleukin-8 in sputum, a marker of airway inflammation, which fell by an estimated 53 percent relative to placebo at six weeks and remained lower at follow-up twelve weeks after treatment stopped. A small trial with an inflammation marker as its endpoint rather than symptoms or lung function.